Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EBIT (2016 - 2025)

Historic EBIT for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $75.5 million.

  • Ironwood Pharmaceuticals' EBIT rose 19444.53% to $75.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.2 million, marking a year-over-year increase of 2415.39%. This contributed to the annual value of $93.1 million for FY2024, which is 10984.99% up from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its EBIT stood at $75.5 million for Q3 2025, which was up 19444.53% from $45.3 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year EBIT high stood at $75.5 million for Q3 2025, and its period low was -$1.1 billion during Q2 2023.
  • For the 5-year period, Ironwood Pharmaceuticals' EBIT averaged around -$14.6 million, with its median value being $45.4 million (2021).
  • Its EBIT has fluctuated over the past 5 years, first surged by 24322.22% in 2021, then plummeted by 204616.66% in 2023.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' EBIT stood at $56.6 million in 2021, then rose by 20.8% to $68.4 million in 2022, then tumbled by 45.02% to $37.6 million in 2023, then fell by 16.22% to $31.5 million in 2024, then soared by 139.7% to $75.5 million in 2025.
  • Its EBIT stands at $75.5 million for Q3 2025, versus $45.3 million for Q2 2025 and -$29.1 million for Q1 2025.